Okay hope everyone having a lovely weekend. Lots of love today. Feeling very blessed 🥰 Going through NNOX tweets from last week. Time to compile threads and bring you highlights. No need to go digging old tweets if I do for you 🤗 FDA, Secondary, and 3P510k. Let’s review..

The NNOX news flow been exceptionally good. I tweet about Fear Uncertainty Doubt and how short sellers leverage friction in news flow to mine some of your gains. NNOX published Form F-1/A to remove friction. Investors have answers.

Form F-1/A Link: https://t.co/RQcYLFMXQO
Form F-1 is over 200 detailed pages. Very concentrated. Everything you need for rest of this month in the document. A few notes for you. NNOX FDA approval uses a third party review organization in 510k process. This is abbreviated to 3P510k.
I covered the 3P510K in thread here: https://t.co/w7zE882CVk

Reference to Eagle eyes: https://t.co/gT779MFX82

We discover in F-1 that 3P510K recommended clearance of Nanox Source. This triggers a 30 day timeline to approval by FDA. However ...
Look at you favorite broker news for NNOX. I look at 3 different broker none of them comment NNOX from 60 to 80 on news that 3P510k recommended FDA approve NNOX device. NNOX get a letter and slide 10% we get headline. But no headline for big pop 🤷‍♂️ that’s the friction.
As cover in Eagle-eyes thread, FDA has 30 days to approve after recommend clearance from 3P510K. Form F-1 state recommend clearance issued 28 DEC. But FDA send letter to ask question. NNOX reply 3 days later 4 JAN. End of Jan FDA send deficiency letter regard predicate devices.
Predicate device is an existing device already approved and currently on market. Something to compare Nanox Source to. When FDA issue deficiency letter it reference comparability with predicate device and Nanox.ARC. This how we must approach 3P510K 30 day window & FDA decision
A thread on 3p510k: https://t.co/Qj80xn00pI

The short thesis destroyed by the recommend clearance. Go back see where NNOX trade before short report. You will recognize the number. Okay you see the number approx the analyst price targets and secondary pricing.
Good question: why has FDA still not approve? I do not know but I share before I think it about classification of device. Class II ideal otherwise it Class III. This is covered in F-1. You may now recognize “de novo”. This is contingency plan Nanox has if FDA classify Class III
What will “de novo” and Class III mean and how likely? It is not likely but def possible. You smart so you like to know risk exposure. That why I mention. I know you too smart to trade blind. But suppose Class III is FDA decision. NNOX goes “de novo” with approx 150 day timeline
Here’s a tweet from thread about 3P510K: https://t.co/MBS6pK4L7n

I typo 99 mean pg 97 but this covered in F-1. Nanox has mapped this out fully and tell you exactly what to expect.

These are two important NNOX points. 3P510K 30 day, FDA classification decision covered for you
30 days tweet: https://t.co/6gFP3QQ92x

Tomorrow FDA will publish all approvals that occur last week. It very possible NNOX is there. Maybe 60% chance
We get the approval news in February given the 3P510K and prompt response from Nanox. We get an earnings report and q&a with NNOX, too. Lots to keep in mind. FDA approval, submit multi source to FDA, progress on MEMS chip facility in Korea with SK Hynix, deals after RSNA, and AI
imo it better to get FDA news next week not tomorrow. Get past secondary. So tomorrow we do not get approval news we Big Smilin because we let them beat up NNOX so we get better entry before approval news official. BUT we careful and cautious because we know Class III possible
Okay back to wifey now she rested after morning of love 😍 I hope this thread help you organize you thoughts about NNOX. My timeline full of gems. Enjoy!
@threadreaderapp please unroll NNOX lovely thread

More from Life

You May Also Like

https://t.co/6cRR2B3jBE
Viruses and other pathogens are often studied as stand-alone entities, despite that, in nature, they mostly live in multispecies associations called biofilms—both externally and within the host.

https://t.co/FBfXhUrH5d


Microorganisms in biofilms are enclosed by an extracellular matrix that confers protection and improves survival. Previous studies have shown that viruses can secondarily colonize preexisting biofilms, and viral biofilms have also been described.


...we raise the perspective that CoVs can persistently infect bats due to their association with biofilm structures. This phenomenon potentially provides an optimal environment for nonpathogenic & well-adapted viruses to interact with the host, as well as for viral recombination.


Biofilms can also enhance virion viability in extracellular environments, such as on fomites and in aquatic sediments, allowing viral persistence and dissemination.
Recently, the @CNIL issued a decision regarding the GDPR compliance of an unknown French adtech company named "Vectaury". It may seem like small fry, but the decision has potential wide-ranging impacts for Google, the IAB framework, and today's adtech. It's thread time! 👇

It's all in French, but if you're up for it you can read:
• Their blog post (lacks the most interesting details):
https://t.co/PHkDcOT1hy
• Their high-level legal decision: https://t.co/hwpiEvjodt
• The full notification: https://t.co/QQB7rfynha

I've read it so you needn't!

Vectaury was collecting geolocation data in order to create profiles (eg. people who often go to this or that type of shop) so as to power ad targeting. They operate through embedded SDKs and ad bidding, making them invisible to users.

The @CNIL notes that profiling based off of geolocation presents particular risks since it reveals people's movements and habits. As risky, the processing requires consent — this will be the heart of their assessment.

Interesting point: they justify the decision in part because of how many people COULD be targeted in this way (rather than how many have — though they note that too). Because it's on a phone, and many have phones, it is considered large-scale processing no matter what.